Bristol Myers cuts PhIII PD-1/LAG-3 trial in colorectal cancer short after drug combo fails analysisnews2023-12-18T12:06:39+00:00December 18th, 2023|Endpoints News|
Sanofi, Boehringer Ingelheim test key immunology drugs in new scleroderma trialnews2023-12-18T12:00:56+00:00December 18th, 2023|Endpoints News|
VC firm Pivotal closes second $389M therapeutics fund to create companies and back public biotechsnews2023-12-18T12:00:33+00:00December 18th, 2023|Endpoints News|
Illumina to divest Grail, after $8 billion purchase two years ago was stymied by antitrustnews2023-12-17T20:37:33+00:00December 17th, 2023|Endpoints News|
Pfizer’s turmoil; FTC’s new target; Aviv Regev Q&A; AstraZeneca’s vaccine gambit; Best of #ASH23; and morenews2023-12-16T11:00:26+00:00December 16th, 2023|Endpoints News|
Merck’s Welireg wins label expansion in kidney cancer despite missing survival datanews2023-12-15T19:36:52+00:00December 15th, 2023|Endpoints News|
FDA converts accelerated to full approval for Padcev-Keytruda combo in bladder cancernews2023-12-15T19:27:21+00:00December 15th, 2023|Endpoints News|
AbbVie winds down five-year, $350M philanthropy pledgenews2023-12-15T18:48:28+00:00December 15th, 2023|Endpoints News|
Europe lines up first CRISPR therapy approvalnews2023-12-15T18:44:55+00:00December 15th, 2023|Endpoints News|
Patent thicket strategy with terminal disclaimers helps block biologic competition, JAMA letter showsnews2023-12-15T18:07:27+00:00December 15th, 2023|Endpoints News|
